Asco 2023
Round Up
The Evaluate Vantage team are back from the 2023 ASCO Annual Meeting reporting on all the big data drops and breakthroughs in cancer care.
Maintaining the momentum
Novocure sinks as Lunar’s limitations become clear
Early first-line lung cancer data mined for datopotamab gold
Dizal heralds a “super-Tagrisso”
Enhertu hits with pan approach
Bicara eyes head and neck niche
Regeneron nips at Bristol’s heels in Lag3
Roche sees Morpheus and takes the red pill
Liver tox casts a pall over Servier’s Indigo readout
Trop2 could validate Merck’s savvy deal with Kelun
Deep and early responses lift hopes at Effector
Pfizer pushes forward in drug-resistant breast cancer
Elevation follows in Astellas’s slipstream
Six months on Gilead/Arcus’s Tigit deflates
A role for immuno-oncology in ovarian cancer at last?
Novartis’s adjuvant breast cancer win comes with caveats
Commands leaves the door open for Geron
Preview – Tigit lives again
Preview – A microcap winner
How we help